#USA #San Francisco #ASCO GU #AVEO Oncology #Tivozanib

AVEO Oncology Presents Vital Tivozanib Research at ASCO GU 2025

AVEO Oncology, the biopharmaceutical entity under LG Chem, recently announced its participation in the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) 2025 meeting. Taking place from February 13-15, 2025, in San Francisco, CA, this noteworthy event will feature significant advancements regarding Tivozanib, an innovative treatment for renal cell carcinoma (RCC).

Edgar Braendle, the Chief Medical Officer at AVEO, expressed enthusiasm about sharing their latest findings with attendees, indicating that they aim to enhance the understanding of Tivozanib within the medical community. This year, two detailed poster presentations are scheduled, which promise to deliver insight regarding the efficacy and patient-reported outcomes associated with Tivozanib in the treatment of RCC.

Presentation Highlights

The presentations slated for ASCO GU are as follows:
1. Integrated Efficacy and Safety Exposure Response Analysis of Tivozanib for RCC
- First Author: Bradley McGregor, MD, Dana-Farber Cancer Institute
- Abstract Number: 461
- Date and Time: Saturday, February 15, 2025, 7:10 AM - 8:10 AM PT and 11:30 AM - 12:45 PM PT
- Poster Board: D29
- Location: Level 1, West Hall

2. Patient-Reported Outcomes for Tivozanib + Nivolumab vs. Tivozanib Monotherapy in RCC (Phase 3 TiNivo-2 Study)
- First Author: Katy Beckermann, MD, PhD, Vanderbilt University
- Abstract Number: 459
- Date and Time: Saturday, February 15, 2025, 7:10 AM - 8:10 AM PT and 11:30 AM - 12:45 PM PT
- Poster Board: D27
- Location: Level 1, West Hall

These presentations aim to shed light on the integrated efficacy of Tivozanib and its corresponding safety profile, aimed at enhancing treatment protocols for RCC patients.

About FOTIVDA® (Tivozanib)

FOTIVDA® is AVEO's flagship product; it represents a next-generation oral treatment targeting vascular endothelial growth factor receptors (VEGFRs). This potent tyrosine kinase inhibitor (TKI) has garnered FDA approval as of March 10, 2021, specifically for adult patients experiencing relapsed or refractory advanced RCC who have undergone two or more systemic therapies. The drug operates selectively on VEGFRs 1, 2, and 3, utilizing a unique formulation to enhance both efficacy and patient tolerance.

AVEO's mission extends further, as they aim not just to market FOTIVDA in the U.S. but to also explore its potential in combination with immunotherapy and other treatments across various oncology domains. As a testimony to their commitment, they continue clinical development in conjunction with leading experts worldwide.

Important Safety Information about FOTIVDA®

Users of FOTIVDA must be aware of critical safety information. Monitoring patients for hypertension is vital, as cases have been recorded in 45% of users, with some severe enough to necessitate treatment alterations. Other side effects include risks of cardiac issues, thromboembolic events, and gastrointestinal complications. These concerns underline the importance of careful patient management in the clinical setting.

For more in-depth information, including comprehensive adverse reactions, it is recommended to consult the prescribing information pertinent to FOTIVDA.

AVEO Oncology, a subsidiary of LG Chem, plays a pivotal role in advancing modern cancer therapies and improving patients’ quality of life during treatment processes.

For more details and updates, visit the official site of AVEO Oncology or engage with them through media channels for the latest on their breakthrough findings presented at this year's ASCO GU meeting.